Patients Want Industry To Minimize Burdens, Augment Comforts Of Device Trial Participation
Executive Summary
Patients and patient advocacy groups at the US FDA's inaugural Patient Engagement Advisory Committee meeting said they need sponsors to minimize the burdens and augment the comforts of trial participation, and get reports on outcomes along the way. Meanwhile, industry groups worried about revealing too much confidential business information, and biasing trial outcomes.
You may also be interested in...
Want Better Clinical Trial Design? Get Early Patient Input, Says FDA
A new guidance document from the US regulatory agency reasons that getting early feedback from patient advocates in the trial-design process could improve enrollment, trial completion and data quality.
FDA Guidance Directs Researchers On Use Of Patient Advocates
A new guidance document from the US agency offers advice on how sponsors can use patient advocates to improve and streamline device clinical trials.
FDA Wrestles With Social Media At Patient Engagement Meeting
US FDA device center's new Patient Engagement Advisory Committee held its second meeting on Nov. 15, focusing on the potential for social media and other patient-generated information to be a source of post-market medical device data.